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Abstract
Background: Although multimodality treatment can induce high rate of remission in many subtypes of non-Hodgkin’s
lymphoma (NHL), significant proportions of patients relapse with incurable disease. The effect of human bone marrow (BM)
mesenchymal stem cells (MSC) on tumor cell growth is controversial, and no specific information is available on the effect of
BM-MSC on NHL.
Methodology/Principal Findings: The effect of BM-MSC was analyzed in two in vivo models of disseminated non-Hodgkin’s
lymphomas with an indolent (EBV2 Burkitt-type BJAB, median survival = 46 days) and an aggressive (EBV+ B lymphoblastoid
SKW6.4, median survival = 27 days) behavior in nude-SCID mice. Intra-peritoneal (i.p.) injection of MSC (4 days after i.p.
injection of lymphoma cells) significantly increased the overall survival at an optimal MSC:lymphoma ratio of 1:10 in both
xenograft models (BJAB+MSC, median survival = 58.5 days; SKW6.4+MSC, median survival = 40 days). Upon MSC injection,
i.p. tumor masses developed more slowly and, at the histopathological observation, exhibited a massive stromal infiltration
coupled to extensive intra-tumor necrosis. In in vitro experiments, we found that: i) MSC/lymphoma co-cultures modestly
affected lymphoma cell survival and were characterized by increased release of pro-angiogenic cytokines with respect to
the MSC, or lymphoma, cultures; ii) MSC induce the migration of endothelial cells in transwell assays, but promoted
endothelial cell apoptosis in direct MSC/endothelial cell co-cultures.
Conclusions/Significance: Our data demonstrate that BM-MSC exhibit anti-lymphoma activity in two distinct xenograft
SCID mouse models of disseminated NHL.
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Introduction
Despite the fact that multimodality treatment, including
combination chemotherapy, radiation, and target-specific mono-
clonal antibodies, such as rituximab, can induce high rate of
remission in many subtypes of non-Hodgkin’s lymphoma (NHL),
significant proportions of patients relapse with incurable disease.
Thus, effective treatments for NHL remain a serious unmet medical
need, also considering that the incidence of NHL continues to rise
[1]. The most prevalent forms of NHL are B-cell malignancies, of
which follicular lymphoma (FL) and diffuse large B-cell lymphoma
(DLBCL) comprise the majority [2]. Burkitt lymphoma is a less
prevalent form of NHL characterized by translocation of the c-myc
oncogene to the Ig heavy chain promoter/enhancer region [3].
Accumulating evidence has shown that, similarly to solid tumors,
the stromal cell component in NHL is not formed by innocent
bystanders in the neoplastic process, but it is composed by cell types
that might actively influence and promote the growth of the
adjacent transformed cells [4–9]. However, the effect of human
bone marrow (BM) mesenchymal stem cells (MSC), which are
considered the stromal progenitor stem cells within the BM, on the
growth of tumoral cells is controversial.
MSC are usually isolated from the adherent mononuclear
fraction of BM aspirates, can proliferate for many passages in
culture and have several properties that make them an attractive
choice as cell therapeutic agents. In fact, they are relatively
nonimmunogenic, although the mechanism of their immune
privilege is not well understood and is a subject of intense study
[10–12]. Because of these properties, MSC exhibit considerable
therapeutic potential in degenerative diseases [13,14]. On the
other hand, regarding their potential therapeutic use in neoplastic
diseases, some studies have suggested that adoptively transferred
MSC could favor tumor engraftment and progression in vivo
[9,12,15]. The deleterious effects could derive from different MSC
characteristics. Indeed, MSC specifically migrate toward sites of
active tumorigenesis, where they could integrate the specialized
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tumor niche, contribute to the development of tumor-associated
fibroblasts and myofibroblasts [16–18], stimulate angiogenesis
[18–20], and promote the growth and drug resistance of both solid
tumors and hematological malignancies [18,21–26].
On these bases, in the present study we have investigated the
effect of BM-derived MSC administration in two models of
disseminated NHL, established by intra-peritoneal (i.p.) injection
in nude-SCID mice of EBV2 Burkitt-type BJAB and EBV+ B
lymphoblastoid SKW6.4 cell lines, characterized by an indolent
(BJAB) and an aggressive (SKW6.4) behavior. Contrary to our
expectation, we found that BM-MSC significantly prolonged the
survival of lymphoma bearing xenografts.
Results
Characterization of the BJAB and SKW6.4 xenograft
models
SCID mice were i.p. injected with a pre-determined optimal
number (26106) of lymphoma (BJAB or SKW6.4) cells. BJAB
xenografts were characterized by peritoneal tumors, which started
to become palpable and measurable by external observation at
18–20 days after injection and steadily progressed until mice death
(Figure 1A). On the other hand, in SKW6.4 xenografts, a tumor
cell mass was hardly palpable at any time point examined.
Histopathological examination of the peritoneal masses showed
that both BJAB- and SKW6.4-derived tumors have a solid pattern
of growth of CD20+ lymphoblastoid cells (Figure 1A). Variable
dissemination of CD20+ lymphoblastoid cells was observed in
lymph nodes and spleen, while bone marrow and kidneys were
usually unaffected (Figure 1B). Moreover, both lymphoma-
bearing xenografts, and in particular SKW6.4 xenografts,
frequently exhibited isolated or massive infiltration of CD20+
lymphoblastoid cells in the liver (Figure 1B).
Of note, in spite of the bigger peritoneal masses in BJAB with
respect to SKW6.4 xenograft mice, the median survival of
SKW6.4 xenografts was significantly (p,0.01) shorter (27 days)
compared to that of BJAB xenografts (47 days; Figure 1C).
Injection of BM-derived MSC significantly prolongs the
survival of both BJAB and SKW6.4 xenografts
To determine the effect of human BM-MSC on the survival of
lymphoma xenografts, groups of SCID mice were i.p. injected
with either BJAB or SKW6.4 cells and, after 4 days, with MSC at
a lymphoma:MSC ratio of 10:1. A group of mice was injected with
MSC alone, as control. Xenograft mice treated with BJAB+MSC
and SKW6.4+MSC showed a significant (p,0.01) increase in
survival as compared to the respective BJAB (Figure 2A) or
SKW6.4 (Figure 2B) xenografts. Of note, increasing the amount
of injected MSC to a lymphoma:MSC ratio of 2:1 did not improve
the overall survival of the BJAB xenografts (Figure 2A).
Moreover, in the BJAB xenograft model, which allowed accurate
measurement of the tumor mass by external inspection, we found
that the improvement in survival was paralleled by a significant
(p,0.05) delay of tumor growth in mice injected with BJAB+MSC
with respect to mice injected with BJAB alone (Figure 2C).
Histopathological examination of the tumoral tissue from the
xenograft SCID mice showed strikingly distinct characteristics
between peritoneal masses developed upon injection with either
lymphoma cells or lymphoma cells+MSC. These analyses were
mostly performed on the BJAB xenograft model because of the
bigger size of the masses, but similar histopathological character-
istics were observed also in the SKW6.4 xenografts. As shown in
Figure 3A, BJAB tumors exhibited a solid pattern of growth with
an inconspicuous stromal meshwork, confirmed by Masson’s
trichrome staining, and few intra-tumor vessels, as detected by
CD31 immunohistochemical staining, an histopathological situa-
tion reminiscent of that observed in the majority of human NHL
[27]. On the other hand, tumoral masses developed in mice co-
injected with BJAB and MSC cells showed a completely different
aspect, characterized by: areas containing stromal bridges
admixed with BJAB cell sheets, as clearly documented by both
H&E and Masson’s trichromic stainings, and intra-tumor stellate
mesenchymal cells often characterized by positivity to a-SMA
(Figure 3B). Of particular interest was the finding that mice co-
injected with BJAB+MSC showed several intra-tumoral foci of
necrosis (Figure 3B), and BJAB cell sheets with foci of necrosis
were often coincident with areas containing a-SMA+ stromal cells
(Figure 3B).
The in vitro co-culture with MSC marginally affects
lymphoma cell survival/proliferation while promotes the
release of angiogenic cytokines
In order to ascertain whether the anti-lymphoma activity of
MSC observed in vivo was due to a direct inhibitory effect of MSC
on lymphoma cells, we have tested whether MSC could modulate
the survival/growth of BJAB and SKW6.4 cells in an in vitro co-
culture system. Cell viability of BJAB cultures showed a moderate
but significant decrease (mean6SD: 2066%, p,0.05), coupled to
apoptosis induction, when BJAB were co-cultured in the presence
of MSC cells, at a lymphoma:MSC ratio of 10:1 (Figure 4A). On
the other hand, cell viability and apoptosis levels of SKW6.4
cultures, were totally unaffected by the presence of MSC
(Figure 4A). In addition, in order to compare the release of
pro-angiogenic cytokines (Table S1), we performed antibody-
based protein array analysis of culture supernatants of: i) SKW6.4
lymphoma cells, ii) MSC, iii) SKW6.4/MSC co-cultured in direct
contact; iv) SKW6.4/MSC co-cultured in transwell plates. As
expected, MSC produced significant levels of several pro-
angiogenic cytokines, some of which (angiogenin, IL-8, CCL2
and VEGF) were significantly up-regulated by the concomitant
presence of SKW6.4 cells (Figure 4B). Both direct and transwell
lymphoma/MSC co-cultures were equally effective in promoting
the cytokine release. The amounts of IL-8 and VEGF were further
measured by ELISA (Figure 4C) and the results were consistent
with those of the protein array analysis (Figure 4B). As shown in
Figure 4C, it should also be noticed that a significant (p,0.05)
increase of the release of IL-8 and VEGF, with respect to MSC
alone, was observed both in MSC/SKW6.4 as well as in MSC/
BJAB co-cultures.
MSC induce the migration of endothelial cells and
promote endothelial cell apoptosis upon direct MSC/
endothelial cell contact
Since MSC release a cocktail of potent pro-angiogenic factors
[28–30], we have next examined the ability of MSC to drive the
migration of endothelial cells. As shown in Figure 5A, MSC
cultures exerted a potent (p,0.01) pro-migratory activity on
endothelial cells, as evaluated in transwell assays. Based on these
observations, in the last group of experiments we have investigated
the effect of a direct interaction between MSC and endothelial
cells. For this purpose, subconfluent HUVEC were seeded in 6-
well plates, and the following day, MSC were added at an
endothelial cell:MSC ratio of 5:1. In a set of experiments, before
the addition of MSC, HUVEC were loaded with the carbocyanine
fluorichrome DiI [31], taking into account that DiI transfer from
different cell types has been described. MSC/HUVEC o-cultures
were then monitored every day by morphological examination
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(under an inverted phase contrast and fluorescence microscope)
and quantification of the overall fluorescence in comparison with
cultures of only HUVEC (Figure 5B). As expected, on day 1,
fluorescence was confined to endothelial cells, while MSC were
completely negative. Over time we observed events of fluorescence
staining diffuse to MSC, indicating that the MSC had merged to
the endothelial cell network (Figure 5B). In parallel, in MSC/
HUVEC co-cultures, we documented a progressive collapse of the
Figure 1. Characterization of the BJAB and SKW6.4 xenograft models. SCID mice were i.p. injected with BJAB or SKW6.4 cells (26106). A,
BJAB but not SKW6.4 xenografts were characterized by peritoneal tumors measurable by external observation. Arrow shows the external border of
the tumor mass. In the insets, macroscopic appearance of the peritoneal masses and histological H&E and CD20 stainings (original magnification,
206) are shown. B, Histopathological examination of necroptic tissue sections obtained from SKW6.4 xenograft showing absent (kidney and bone
marrow), isolated (arrows; spleen and liver) or massive (lymph node and liver) infiltration of CD20+ human lymphoid cells. Original magnification, 206.
C, Kaplan-Meier survival analysis of the NHL xenograft models. The survival percentage of mice injected with BJAB (n = 15) or SKW6.4 (n = 15) cells was
measured from the day of lymphoma cell injection until the day of death. Asterisk, p,0.01.
doi:10.1371/journal.pone.0011140.g001
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endothelial cell monolayer, with the prevalence of dead endothe-
lial cells nearby the MSC and a significant increase of apoptotic
cells, quantified by Annexin-V/PI double staining (Figure 5B–C).
Unfortunately, in these sets of experiments we were unable to
perform tripartite experiments with the addition also of lymphoma
cells, for technical problems mainly due to differences in culture
media requirements.
Discussion
Previous in vivo studies have evaluated the effect of MSC in
animal models of hematological malignancies confined in
subcutaneous gel devices [14,15,32]. Taking into account that
the majority of NHL mainly progresses as a systemic malignancy,
in this study we have developed and described two animal models
that allowed us the investigation of the activity of MSC against
NHL in xenografts bearing disseminated tumors. Indeed, after i.p.
injection, malignant BJAB and SKW6.4 lymphoma cells formed
tumor masses, with frequent dissemination to liver and abdominal
lymph nodes.
The major finding of the present study is that a single MSC
injection, at MSC:tumor cell ratio as low as 1:10, significantly
prolonged the survival in animals with indolent (BJAB) and
aggressive (SKW6.4) lymphomas. This observation was particu-
larly encouraging since it was obtained in disseminated NHL
bearing xenografts, that, in our opinion, are more relevant than
the subcutaneous NHL models employed in previous studies
[14,15,32]. Of note, increasing the number of MSC, up to
MSC:tumor cell ratio of 1:2, did not result in a significant
improvement of the therapeutic efficacy of MSC. The injection of
MSC delayed the development of the peritoneal tumoral masses of
the NHL xenografts, and at necroscopic analysis, tumor specimens
developed in the absence or presence of MSC showed significant
histological differences, which can be recapitulated as follow: while
BJAB- and/or SKW6.4-derived peritoneal masses showed the
typical faint capillary network also described in human NHL [27],
the presence of MSC promoted a diffuse increase in a-SMA+ cell
incorporation throughout the stromal compartment at variance of
the scant SMA+ perivascular pattern predominantly observed in
the absence of MSC. Moreover, massive areas of intra-tumoral
necrosis were preferentially observed in lymphoma+MSC injected
animals and likely account for the reduced tumor masses
characterizing these mice with respect to animals injected with
lymphoma cells alone.
In the attempt to elucidate the mechanism(s) by which MSC
exert anti-lymphoma activity in vivo, we have performed a series of
in vitro experiments in co-culture systems. The results derived from
these experiments tend to exclude a significant direct cytotoxic
effect of MSC on lymphoma cells, since MSC moderately
inhibited the viability of BJAB but did not exhibit any appreciable
effect on SKW6.4 cell survival/growth. Of interest, the ability of
MSC cultures of secreting high levels of angiogenic cytokines, such
as VEGF, IL-8, angiogenin and CCL2, was significantly (p,0.01)
enhanced by the concomitant presence of lymphoma cells.
Consistently with their ability of release several pro-angiogenic
cytokines, MSC potently promoted the migration of endothelial
cells in transwell assays. However, when MSC were directly co-
cultured with endothelial cells, we observed a significant induction
of endothelial cell apoptosis. In this respect, our current findings
are in agreement with those of other Authors who have
demonstrated that MSC under certain circumstances might exert
anti-angiogenic activity in highly vascularized Kaposi sarcomas
[33], as well as in normal endothelial cell cultures in vitro [34].
Thus, although we were unable to document the relevance of these
in vitro data in our animal models, our findings suggest the
existence of a complex interplay between MSC, lymphoma cells
and endothelial cells, characterized by: i) a significant release of
pro-angiogenic/pro-migratory cytokines by MSC, which is
enhanced by the presence of lymphoma cells; ii) a potent
chemotactic activity of MSC on endothelial cells, followed by a
cytotoxic activity of MSC on endothelial cells, which required the
MSC/endothelial cell contact.
Figure 2. Injection of BM-derivedMSC prolonged the survival of
BJAB and SKW6.4 xenografts. SCIDmice were i.p. injectedwith either
BJAB (n= 10) or SKW6.4 (n= 10) cells and, after 4 days, with MSC at a
lymphoma:MSC ratio of 10:1. As control, a group of mice (n= 10) was
injected with MSC alone. Kaplan-Meier analysis of the NHL xenograft
models, comparing the survival of mice injected with BJAB6MSC (A) or
SKW6.46MSC (B). In BJAB xenograft mice, results obtained in a group of
mice (n= 10) injected with MSC at a lymphoma:MSC ratio of 2:1 are also
shown (A). The survival percentage was measured from the day of
lymphoma cell injection until the day of death. Asterisk, p,0.05 with
respect to BJAB or SKW mice. C, Peritoneal tumors were measured every
week, until animal death, as described in the Material and Methods
section.Results are means6SD. Asterisk, p,0.05.
doi:10.1371/journal.pone.0011140.g002
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Figure 3. Increased presence of fibrovascular network, necrotic areas and a-SMA+ cells in tumor tissues of xenograft lymphomas
co-injected with MSC. Sections of peritoneal masses from BJAB (A) and BJAB+MSC (B) xenograft mice were analyzed after H&E and Masson’s
trichromic stainings, and immunophenotypical analyses performed with antibodies anti-CD31 or anti-aSMA, as indicated. In H&E staining sections,
asterisks indicate small foci of necrosis within tumor masses (B). In Masson’s trichromic stained sections, collagen fibers are colored in blue
(arrowheads) and evidence a thin and inconspicuous stromal meshwork among the solid pattern of the tumor in A, or a more diffuse and thick
stromal architecture in B. CD31+ endothelial cells and a-SMA myofibroblast-like cells are colored in brown (arrows in A and B). Original magnification
206.
doi:10.1371/journal.pone.0011140.g003
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We are also aware that extrapolation of a given animal model to
clinically relevant situations should be considered with extreme
caution. In particular, we should remember that an important
limitation of our study is represented by the fact that the anti-
tumoral immune response is not valuable in our SCID model, but
likely it is important in the overall effect of MSC on tumor growth.
In fact, it has been shown that the immunosuppressive effect of
MSC might favor tumor growth in allogeneic animals [12].
Although some controversial data are present on the role of MSC
in cancer development and/or therapy [35,36], several novel
conclusions can be summarized from our study: i) the in vitro
interaction of BM-derived MSC and lymphoma cells poorly
predicts the in vivo effect of MSC on the survival of xenograft
bearing animals; ii) MSC significantly modulate the stromal
network of lymphomas in vivo, by increasing the number of a-
SMA-positive cells and inducing an increase of intratumor
necrosis; iii) MSC promote endothelial cell migration in vitro
followed by endothelial cell death upon MSC/endothelial direct
cell contact.
Materials and Methods
Cells
SKW6.4 and BJAB cell lines were obtained from DSMZ
(Deutsche Sammlung von Mikroorganismen und Zellkulturen
GmbH, Braunschweig, Germany) or purchased from the Amer-
ican Type Culture Collection (ATCC, Manassas, VA), and
cultured in RPMI-1640 containing 10% fetal bovine serum
(FBS; Gibco BRL, Gaithersbrg, MD). Human BM-derived MSC
and human umbilical vein endothelial cells (HUVEC) were
purchased from Lonza (Walkersville, MD). BM-MSC were
routinely cultured in MSC-Growth Medium (MSC-GM, Lonza).
HUVEC were grown on 0.2% gelatin-coated tissue culture plates
in M199 endothelial growth medium supplemented with 20%
FBS, 10 mg/ml heparin, and 50 mg/ml ECGF (all from Lonza) as
previously described [37]. In all experiments, MSC and HUVEC
were used between the 3rd and 6th passage in vitro.
NHL mouse xenograft models
Female C.B-17 SCID mice (4 weeks-old) were obtained from
Charles River Laboratories (Hollister, CA) and were maintained in
accordance with the Guide for the Care and Use of Laboratory
Animals. Mice were housed in micro-isolator cages with free access
to food and water. The procedures involving animals and their
care were conducted in accordance with National Institutes of
Health Guide for the Care and Use of Laboratory Animals and
were approved by the Institutional Animal Care Committee at the
University of Trieste (approval number of the Italian Ministry of
Health 191/2008-D). In particular, any effort was put to avoid
unnecessary pain of the animals. SKW6.4 or BJAB (26106) cells
were harvested, suspended in PBS, and i.p. injected into 6-week-
old mice. After 4 days, lymphoma xenograft mice were
randomized into groups (at least 10 mice for each group), and
dosed i.p. with vehicle (PBS) or MSC (26105 or 16106,
corresponding at a lymphoma:MSC ratio of 10:1 and 2:1
respectively). In a group of SKW6.4 mice (n = 10), MSC were
injected at 12 days post SKW6.4 injection.
Animals were monitored daily for changes in weight, side effects
of the treatment or signs of any sickness. Tumor growth was
determined by calliper measurements of two orthogonal axes and
the tumor volume was calculated by the formula: (p/6)6a26b,
wherein a is the shorter and b is the longer axis; the tumor density
was assumed to be equal to one. Survival was calculated as the
duration of the animal’s life span from the inoculation of
lymphoma cells until death. Necropsy was carried out to
determine macroscopic extent and histological characteristics of
the peritoneal masses. In addition, major organs including heart,
kidneys, femur (for bone marrow), liver, spleen, nodes were
harvested for microscopic examination and to evaluate the pattern
of dissemination of engraftment.
Histopathological and immunophenotypical analysis
Animal specimens were fixed in 10% buffered-formalin solution
and embedded in paraffin. For morphological analysis, 4-mm-thick
sections were cut from paraffin blocks and stained with
hematoxylin-eosin. Immunohistochemistry was performed by the
means of the streptavidin-biotin-peroxidase complex method using
the following primary mAbs for: CD20, a-SMA and CD31 (Dako,
Glostrup, Denmark). 3-39diaminobenzidine was used as a
chromogen (Vector Laboratories, Burlingame, CA). For determi-
nation of collagen content, the sections were stained with Masson’s
trichrome. After the stainings, the slides were examined under a
Leica DM2000 optical microscope and microphotographs were
taken using a Leica DFC320 digital camera.
Co-culture experiments
For lymphoma/MSC co-culture in vitro experiments, MSC were
seeded in 6 well-plates and the following day, either BJAB or
SKW6.4 cells were added to the MSC cultures at a lympho-
ma:MSC ratio of 10:1. Co-cultures were carried out for up
96 hours, in lymphoma cell medium. In some experiments, co-
cultures were performed by using 24-Transwell plates (3.0 mm,
pore size; Corning Costar, Cambridge, MA), with MSC seeded in
the lower compartment and lymphoma cells added in the upper
compartment.
For endothelial/MSC co-cultures, HUVEC were seeded in 6-
well plates and the following day, MSC were added at a
HUVEC:MSC ratio of 5:1. Co-cultures were carried out for up
5 days in HUVEC medium. In some experiments, before addition
of MSC, HUVEC were loaded with the carbocyanine fluoro-
chrome DiI (1,19dioctadecyl-3,3,39,39tetramethylindocarbocya-
nine perchlorate; Molecular Probes, Invitrogen, Merelbeke,
Belgium). DiI is a lipophilic molecule that incorporates in the
cell membrane, and has the following spectral characteristics:
absorption maximum at 549 nm and an emission maximum at
565 nm. For this purpose, HUVEC were incubated with 50 mg/
Figure 4. The in vitro co-culture with MSC marginally affects lymphoma cell survival and promotes the release of angiogenic
cytokines. BJAB and SKW6.4 cells were cultured in the absence or presence of MSC, at a lymphoma:MSC ratio of 10:1. A, After 96 hours of culture,
lymphoma cell apoptosis was analyzed by double Annexin V/PI staining. B, Culture supernatants were harvested from: SKW6.4 lymphoma cells alone,
MSC alone, SKW6.4/MSC direct co-cultures and SKW6.4/MSC transwell co-cultures. The release of pro-angiogenic cytokines was assessed in the
culture supernatants by using a proteome profiler human angiogenesis array. The circles on the membranes highlight four cytokines (angiogenin, IL-
8, CCL2 and VEGF) released by MSC, which are significantly up-regulated by the concomitant presence of SKW6.4 cells. Similar results were obtained
from three independent experiments and results from one of them are shown. The bar chart reports the results of the densitometric analyses of
membranes. Abbreviations of the analyzed cytokines are defined in Table S1. Asterisk, p,0.05. C, Levels of IL-8 and VEGF were measured in the
culture supernatants of the indicated cultures by ELISA. Data are reported as mean6SD of four independent experiments, each performed in
duplicate. Asterisk, p,0.01.
doi:10.1371/journal.pone.0011140.g004
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ml DiI for 2 hours before performing MSC:endothelial cell co-
cultures. Morphology of the HUVEC cultures and HUVEC/
MSC co-cultures was observed periodically over time under an
inverted phase contrast and fluorescence microscope and the
overall fluorescence was quantified with a fluorescence plate
reader.
Apoptosis assay
For analysis of apoptosis, cells were double stained with
Annexin V-fluorescein isothiocyanate (Alexis Biochemicals, Lau-
sen, Switzerland) and propidium iodide (PI), according to the
instructions of the manufacturer, and analyzed using a FACScan
flow cytometer (Becton-Dickinson, San Jose, CA), as previously
described [38]. To avoid non-specific fluorescence from dead cells,
live cells were gated tightly using forward and side scatter. In
particular, for HUVEC and MSC/HUVEC cultures, to analyze
the degree of apoptosis in the entire cell population, substrate-
attached cells were harvested by trypsin treatment and pooled with
floating cells for the staining.
Proteome profiler array and enzyme-linked
immunosorbent assays
Culture supernatants were analyzed by using the proteome
profiler human angiogenesis array (R&D Systems, Minneapolis,
MN), according to the manufacturer’s instructions. Briefly, equal
amounts of culture supernatants were diluted and mixed with a
cocktail of biotinylated angiogenesis-detection antibodies and
incubated with the (capture) antibody membranes overnight at
4uC. After washing of unbound material, the membranes were
incubated with HRP-conjugated streptavidin. Chemiluminescence
was used for signal detection. Staining intensity of dots were
determined with ImageQuant software (Molecular Dynamics) and
expressed as arbitrary units.
Enzyme-linked immunosorbent assays (ELISA) for IL-8 and
VEGF analyses were performed by using commercially available
ELISA kits (R&D Systems). Assays were performed in duplicate
and according to the manufacturer’s instructions. Results were
read at an optical density of 450 nm using an Anthos 2010 ELISA
reader (Anthos Labtec Instruments, Wals Salzburg, Austria).
Endothelial cell migration assay
Cell migration assay was performed in 24-well Transwell plates
(8.0 mm, pore size) as previously described [39]. MSC were seeded
in HUVEC culture medium into the lower chamber of transwell
plates and, after 72 hours, 0.256105 HUVEC per well were added
to the top chambers in 100 ml medium. After 5 hours at 37uC, the
upper sides of the filters were carefully washed with PBS, and cells
remaining on the upper faces were removed with a cotton wool
swab. Transwell filters were then fixed and stained using crystal
violet. Cells that had migrated (on the bottom side of the filter)
were counted using light microscopy. The average number of
migrating cells per field was assessed by counting at least four
random fields per filter. Each experiment was done in duplicate.
Statistical analysis
Results from at least three independent experiments are
reported as the means6SD and analyzed for statistical significance
by the two-tail Student’s t-test and Mann-Witney rank-sum test.
Analysis of survival data was carried out with GraphPad Prism
version 4 (GraphPad Software); in particular differences in survival
between treatment groups were calculated using the Kaplan-Meier
curve and survival distribution of the treated and control groups
was compared using the log-rank test. Differences were considered
significant when p value was ,0.05.
Supporting Information
Table S1 Human angiogenesis-related proteins and cytokine
array coordinates.
Found at: doi:10.1371/journal.pone.0011140.s001 (0.09 MB
DOC)
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